Plasma proteomics identifies CRTAC1 as a biomarker for osteoarthritis severity and progression. (4th August 2022)

• Record Type: Journal Article
• Authors: Szilagyi, Ingrid A; Vallerga, Costanza L; Boer, Cindy G; Schiphof, Dieuwke; Ikram, M Arfan; Bierma-Zeinstra, Sita M A; van Meurs, Joyce B J
• Is Part Of: Rheumatology. Volume 62:Number 3(2023)
• Page Start: 1286
• Page End: 1295
• Publication Date: 2022-08-04
• Subjects: biomarkers -- osteoarthritis -- severity -- progression -- inflammation -- metabolic pathway; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keac415
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objectives: The aim of this study was to identify biomarkers for radiographic OA severity and progression acting within the inflammation and metabolic pathways. Methods: For 3517 Rotterdam Study participants, 184 plasma protein levels were measured using Olink inflammation and cardiometabolic panels. We studied associations with severity and progression of knee, hip and hand OA and a composite overall OA burden score by multivariable regression models, adjusting for age, sex, cell counts and BMI. Results: We found 18 significantly associated proteins for overall OA burden, of which 5 stayed significant after multiple testing correction: circulating cartilage acidic protein 1 (CRTAC1), cartilage oligomeric matrix protein (COMP), thrombospondin 4, IL-18 receptor 1 (IL-18R1) and TNF ligand superfamily member 14. These proteins were also associated with progression of knee OA, with the exception of IL-18R1. The strongest association was found for the level of CRTAC1, with 1 s .d . increase in protein level resulting in an increase of 0.09 (95% CI 0.06, 0.12) in the overall OA Kellgren–Lawrence sum score ( P = 2.9 × 10 −8 ) in the model adjusted for age, sex, BMI and cell counts. This association was also present with the severity of OA in all three joints and progression of knee OA and was independent of BMI. We observed a stronger association for CRTAC1 with OA than for the well-known OA biomarker COMP. Conclusion: We identified several compelling biomarkers reflecting the overall OA burden and the increased risk for OA progression. CRTAC1 was the most compelling and robust biomarker for OA severity and progression. Such a biomarker may be used for disease monitoring.